A Study of LY3526318 in Healthy Participants

Inclusion Criteria: Part A Cohorts: \- Healthy male participants (including self-reported surgically sterile males) must agree to the following: * When engaging in sex with Women of Child-Bearing Potential (WOCBP) both the male participant and his female partner must use highly effective contraception consisting of 2 forms of birth control (1 of which must be a male barrier method such as a latex or polyurethane condom) from start of dosing throughout the clinical study period, and for 90 days after the final study drug administration * Nonsurgically sterile male participants must not donate sperm at any time from start of dosing until 90 days beyond the administration of study drug All Part A and Part B Cohorts: * Female participants must be nonpregnant and not lactating, or of nonchildbearing potential (either surgically sterilized \[e.g. tubal occlusion, hysterectomy, bilateral salpingectomy\] or physiologically incapable of becoming pregnant, or postmenopausal with amenorrhea for at least 12 consecutive months). Healthy female participants of child-bearing potential who have a fertile male sexual partner must be willing and able to practice effective contraception from admission to 30 days after the final visit. Sexually active participants must use a combination of 2 of the following methods of contraception, including at least 1 so-called 'barrier' method: * Hormonal contraceptive (oral, transdermal patches, vaginal or injectable) * Intrauterine device with or without hormones * Condom ('barrier' method) * Diaphragm or cervical cap * Sexual abstinence * Have a body mass index 18 to 32 kilograms per square meter (kg/m²) Exclusion Criteria: * Are currently enrolled in a clinical study involving an investigational product or any other type of medical research judged not to be scientifically or medically compatible with this study * Have a history or presence of medical illness including, but not limited to, any cardiovascular, hepatic, respiratory, hematological, endocrine, psychiatric or neurological disease, convulsions, or any clinically significant laboratory abnormality * In the opinion of the investigator are considered to be a danger to themselves * Have an abnormality in the 12-lead electrocardiogram (ECG) * Have a history of clinically significant multiple or severe drug allergies or severe post treatment hypersensitivity reactions * Have donated blood of more than 500 milliliter (mL) within the previous month * Are unwilling to stop alcohol and caffeinated beverage consumption and smoking/use of tobacco while resident in the CRU * Have an average weekly alcohol intake that exceeds 21 units per week (1 unit = 12 ounces (oz) or 360 mL of beer; 5 oz or 150 mL of wine; 1.5 oz or 45 mL of distilled spirits * Have an abnormal blood pressure * Participants with a history of drug abuse * Have received treatment with biologic agents (such as monoclonal antibodies, including marketed drugs) within 3 months or 5 half-lives (whichever is longer) * Are unwilling to comply with the required dietary restrictions